Mansfield, Colin

ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?

Petrov, D., Mansfield, C., Moussy, A., & Hermine, O. (2017) · Frontiers in Aging Neuroscience

Amyotrophic Lateral Sclerosis ResearchAlzheimer's disease research and treatments

Cited by 451

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE

Mast cells and histamineGastrointestinal Tumor Research and Treatment

Cited by 421

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial

Vermersch, P., Brieva-Ruiz, L., Fox, R. J., Paul, F., Ramio-Torrenta, L., Schwab, M., Moussy, A., Mansfield, C., Hermine, O., Maciejowski, M., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 74

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Dubois, B., López‑Arrieta, J., Lipschitz, S., Doskas, T., Spiru, L., Moroz, S., Venger, O., Vermersch, P., Moussy, A., Mansfield, C. D., et al. (2023) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 10